The Indian Pharmaceutical Market (IPM) continues to showcase robust growth, with an impressive 8.7% increase in August 2025, culminating in sales worth Rs 20,984 crore. These findings, as reported by the latest PharmaTrac Industry Report by Pharmarack, shed light on the dynamic landscape of the pharmaceutical industry in India.
Steady Expansion Amidst Changing Dynamics
In terms of units, the market saw a 1.2% growth, indicating sustained demand despite some stagnation in volume. The growth in August was primarily fueled by price increments, buoyed by the introduction of new products and the seasonal demand for specific therapies.
Therapeutic Triumphs
The respiratory segment emerged as a frontrunner in August, recording a remarkable growth rate of 17.3%, driven by seasonal influences. Antineoplastic drugs witnessed a substantial surge of 19.7%, while urology and cardiac therapies expanded by 14.6% and 13.2% respectively. Additionally, blood-related treatments saw a 10% rise, anti-diabetic drugs grew by 9.4%, and gastrointestinal products reported a 7.1% increase. Vitamins, minerals, neuro/CNS therapies, dermatology, and anti-infectives also experienced growth, with vaccines notably rebounding with a 21.4% growth rate.
Corporate Prowess and Brand Domination
Sun Pharma retained its leading position in the market with sales amounting to ₹19,542 crore, marking a significant 13.7% growth. Following closely, Abbott achieved sales of ₹13,723 crore, reflecting an 8.4% increase, while Mankind Pharma showcased robust performance with sales of ₹13,326 crore and a growth rate of 9.6%. Other key pharmaceutical companies such as Cipla, Alkem, Intas, Torrent, Lupin, Dr. Reddy’s, and Zydus also demonstrated healthy growth ranging from 7% to 13%. The top 20 list further included names like Macleods, Aristo, Emcure, GSK, Glenmark, USV, IPCA, Micro Labs, Pfizer, and Eris Lifesciences, all of which exhibited positive momentum in August.
At the brand level, stalwarts like Augmentin (GSK), Glycomet GP (USV), Pan (Alkem), and Mixtard (Abbott) continued to dominate the market. Himalaya’s Liv.52 and Alkem’s Pan D witnessed notable growth rates of 13.9% and 15.3% respectively. Innovative therapies like Abbott’s Ryzodeg and Thyronorm also made a mark with growth rates of 17.4% and 16.3% respectively. The top-selling list further featured brands such as Clavam, Monocef, Udiliv, Zerodol SP, Betadine, Telma, Manforce, Cilacar, Electral, Ultracet, and Duolin.
Key Takeaways:
– The Indian Pharma Market exhibited a robust 8.7% growth in August 2025, reaching sales of Rs 20,984 crore.
– Respiratory, antineoplastic, and cardiac therapies were among the top performers in terms of growth rates.
– Sun Pharma, Abbott, and Mankind Pharma emerged as leading companies in the market, showcasing significant sales figures and growth percentages.
– Key brands such as Augmentin, Glycomet GP, Pan, and Mixtard continued to dominate the market, with innovative therapies also gaining traction.
The pharmaceutical landscape in India continues to evolve, driven by innovation, market dynamics, and evolving consumer needs. The growth witnessed in August 2025 signifies the resilience and adaptability of the industry, paving the way for further advancements and breakthroughs in healthcare.
Read more on medicaldialogues.in